Detalhe da pesquisa
1.
Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.
Blood
; 2024 May 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38776510
2.
The role of B cells in the pathogenesis of graft-versus-host disease.
Blood
; 114(24): 4919-27, 2009 Dec 03.
Artigo
Inglês
| MEDLINE | ID: mdl-19749094
3.
CCC meets ICU: redefining the role of critical care of cancer patients.
BMC Cancer
; 10: 612, 2010 Nov 08.
Artigo
Inglês
| MEDLINE | ID: mdl-21059210
4.
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Am Soc Clin Oncol Educ Book
; 35: e387-98, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-27249745
5.
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Haematologica
; 90(10): 1357-64, 2005 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-16219572
6.
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
J Clin Oncol
; 30(9): 980-8, 2012 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-22331940
7.
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.
Blood
; 108(6): 2127-30, 2006 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16728696